Download your interactive insomnia conversation starter
Click on the button below to download the interactive PDF of the insomnia conversation starter.
How can the insomnia conversation starter help?
- Define the type of insomnia
Treatment of insomnia depends on whether it is acute or chronic. Diaries and questionnaires can help patients explain their concerns and give you, as a healthcare professional, the information you need to advise them.
Grouped questions by topics
The insomnia conversation starter contains just a few questions, grouped by topic, to help your patient quickly summarise their sleep routine and identify challenges.
- Make the most of your consultation time
Completion by a patient ahead of their appointment, or with you during the appointment, can help make the most of your consultation time.
Patient support material from Idorsia Pharmaceuticals UK Ltd.
QUVIVIQ™▼(daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1
References
1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated May 2025. Accessed June 2025.
4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.
